Evidence map›Paper›PMID 29859231›Full record

ArticleJournal of immunological methods2018

A simple and enzyme-free method for processing infiltrating lymphocytes from small mouse tumors for ELISpot analysis.

Adam M Swartz, Elizabeth Reap, Pamela Norberg, Robert Schmittling, Sylvia Janetzki, Luis Sanchez-Perez, John H Sampson

Open access · hybridAbstract read
In one paragraph

Article in Journal of immunological methods, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Adam M SwartzDuke Brain Tumor Immunotherapy Program, Department of Neurosurgery, Duke University Medical Center, DUMC Box 3050, 303 Research Drive, 220 Sands Building, Durham, NC 27710, USA; The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC, USA; Department of Pathology, Duke University Medical Center, Durham, NC, USA. Electronic address: adam.swartz@duke.edu.
Elizabeth ReapDuke Brain Tumor Immunotherapy Program, Department of Neurosurgery, Duke University Medical Center, DUMC Box 3050, 303 Research Drive, 220 Sands Building, Durham, NC 27710, USA; The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC, USA.
Pamela NorbergDuke Brain Tumor Immunotherapy Program, Department of Neurosurgery, Duke University Medical Center, DUMC Box 3050, 303 Research Drive, 220 Sands Building, Durham, NC 27710, USA; The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC, USA.
Robert SchmittlingDuke Brain Tumor Immunotherapy Program, Department of Neurosurgery, Duke University Medical Center, DUMC Box 3050, 303 Research Drive, 220 Sands Building, Durham, NC 27710, USA; The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC, USA.
Sylvia JanetzkiZellNet Consulting, Inc, 555 North Avenue, Suite 25-S, Fort Lee, NJ 07024, USA. Electronic address: sylvia@zellnet.com.
Luis Sanchez-PerezDuke Brain Tumor Immunotherapy Program, Department of Neurosurgery, Duke University Medical Center, DUMC Box 3050, 303 Research Drive, 220 Sands Building, Durham, NC 27710, USA; The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC, USA.
John H SampsonDuke Brain Tumor Immunotherapy Program, Department of Neurosurgery, Duke University Medical Center, DUMC Box 3050, 303 Research Drive, 220 Sands Building, Durham, NC 27710, USA; The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC, USA; Department of Pathology, Duke University Medical Center, Durham, NC, USA. Electronic address: john.sampson@duke.edu.
Duke University Hospital · USDuke Medical Center · US

Funding

Targeted Alpha-Particle Radiotheraphy of Brain Tumors with 211At-81C6 AntibodyP50CA190991 · NCI · DUKE UNIVERSITY · PI SAMPSON, JOHN H. · 2014 to 2023
$20.8M
Brain tumors with regulatory T-cells treated with EGFRvIII-specific T-cellsR01CA177476 · NCI · DUKE UNIVERSITY · PI SAMPSON, JOHN H. · 2013 to 2017
$2.3M
EGFRvIII-targeted Bispecific T cell Engagers for brain tumorsR01NS085412 · NINDS · DUKE UNIVERSITY · PI SAMPSON, JOHN H. · 2013 to 2017
$2.0M
CCL3 as a Developmental Therapeutic to Enhance Brain Tumor TherapyR01NS099463 · NINDS · DUKE UNIVERSITY · PI SAMPSON, JOHN H. · 2017 to 2021
$1.7M
Brain Tumor Targeting Using Tumor-Specific NeuroimmunologyR01NS086943 · NINDS · DUKE UNIVERSITY · PI SAMPSON, JOHN H., YAN, HAI · 2014 to 2017
$1.4M
Clinical Neuroimmunology of Vaccines in Brain TumorsR01NS116888 · NINDS · DUKE UNIVERSITY · PI LI, QIJING, SAMPSON, JOHN H. · 2021 to 2022
$802k
NCI NIH HHS P50 CA190991NCI NIH HHS R01 CA177476NINDS NIH HHS R01 NS085412NINDS NIH HHS R01 NS086943NINDS NIH HHS R01 NS099463NINDS NIH HHS R01 NS116888
6 · The paper itself

Abstract

The ELISpot assay prevails as one of the most sensitive and meaningful assays for the detection of antigen-specific, effector immune responses. Acquisition of cellular analyte for ELISpot analysis is typically not problematic when derived from tissues enriched in lymphocytes (e.g., lymphoid organs and blood); however, cell processing becomes more difficult when lymphocytes represent only a very minor population relative to the source tissue, especially when the source tissue is in limited supply (e.g., small mouse tumors). Traditional enzymatic-based methods for dissociating tumors often result in poor yields, inconsistent lymphocyte enrichment, and can have deleterious effects on lymphocyte phenotype and function. To address these limitations, we have developed an enzyme-free protocol for processing tumor infiltrating lymphocytes (TILs) from small mouse tumors, which enables the enumeration of antigen-specific effector lymphocytes using ELISpot analysis. This procedure is predicated on the dissociation of tumor tissue using gentle agitation with a paddle blender followed by a brief in vitro culture period to remove adherent cells, as well as to revive lymphocytes from a non-responsive state. Although this method is demonstrated with mouse intracerebral tumors, we have found that this protocol is applicable to peripheral tumors and may likely extend to alternative tissue sources wherein lymphocytes exist in low numbers.

Indexed as

Enzyme-Linked Immunospot AssayAnimalsCell SeparationEnzymesLymphocytes, Tumor-InfiltratingMiceMice, Inbred C57BLNeoplasmsT-LymphocytesEnzymesELISpotTILTumor infiltrating lymphocyte

Identifiers

PMID29859231
PMCPMC6037182
OpenAlexW2807691532

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.